Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.63 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.63 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.63 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.60 |
| ▸ | HRH2 | P25021 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28601081 | 0.76 | SLC6A2 (0.78) | SLC6A2HRH2HTR2AHTR2BSLC6A3 | |
| SCHEMBL28601084 | 0.76 | SLC6A2 (0.78) | SLC6A2HRH2HTR2AHTR2BSLC6A3 | |
| SCHEMBL28438949 | 0.76 | SLC6A2 (1.00) | SLC6A2HRH2HTR2AHTR2BSLC6A3 | |
| SCHEMBL28438946 | 0.76 | SLC6A2 (1.00) | SLC6A2HRH2HTR2AHTR2BSLC6A3 | |
| SCHEMBL28591137 | 0.72 | SLC6A2 (0.93) | SLC6A2HRH2HTR2AHTR2BSLC6A3 | |
| SCHEMBL10326519 | 0.71 | CHRNA3 (0.56) | CHRNB2CHRNA5CHRNB4CHRNA3 | |
| SCHEMBL10326825 | 0.71 | CHRNA3 (0.56) | CHRNB2CHRNA5CHRNB4CHRNA3 | |
| SCHEMBL10326841 | 0.71 | CHRNA3 (0.56) | CHRNB2CHRNA5CHRNB4CHRNA3 | |
| SCHEMBL24466889 | 0.70 | CHRNB1 (0.53) | CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL29770146 | 0.70 | CHRNA3 (0.45) | CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402935-A1 | HETEROCYCLIC COMPOUND | FIMECS, INC. (JP) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402935-A1 | HETEROCYCLIC COMPOUND | IRAK1, IRAK2, IRAK4 | CHRNB2 4774/4885CHRNA5 4355/4885CHRNB4 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.